Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles.
Lai, Wai; Sun, PJ; Zhang, J; Jennings, Adam; Lalor, Patricia; Hubscher, Stefan; McKeating, Jane; Adams, David

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 05. Jan. 2019
Expression of DC-SIGN and DC-SIGNR on Human Sinusoidal Endothelium

A Role for Capturing Hepatitis C Virus Particles

Wai K. Lai,* Phoebe J. Sun,* Jie Zhang,† Adam Jennings,† Patricia F. Lalor,* Stefan Hubscber,* Jane A. McKeating,† and David H. Adams*

From the Liver Research Group† and the Hepatitis C Virus Laboratory,* Medical Research Council Centre for Immune Regulation, Institute of Biomedical Research, University of Birmingham Medical School, Edgbaston, Birmingham, United Kingdom

Hepatic sinusoidal endothelial cells are unique among endothelial cells in their ability to internalize and process a diverse range of antigens. DC-SIGNR, a type 2 C-type lectin expressed on liver sinusoids, has been shown to bind with high affinity to hepatitis C virus (HCV) E2 glycoprotein. DC-SIGN is a closely related homologue reported to be expressed only on dendritic cells and a subset of macrophages and has similar binding affinity to HCV E2 glycoprotein. These receptors function as adhesion and antigen presentation molecules. We report distinct patterns of DC-SIGNR and DC-SIGN expression in human liver tissue and show for the first time that both C-type lectins are expressed on sinusoidal endothelial cells. We confirmed that these receptors are functional by demonstrating their ability to bind HCV E2 glycoproteins. Although these lectins on primary sinusoidal cells support HCV E2 binding, they are unable to support HCV entry. These data support a model where DC-SIGN and DC-SIGNR on sinusoidal endothelium provide a mechanism for high affinity binding of circulating HCV within the liver sinusoids allowing subsequent transfer of the virus to underlying hepatocytes, in a manner analogous to DC-SIGN presentation of human immunodeficiency virus on dendritic cells. (Am J Pathol 2006, 169:200–208; DOI: 10.2353/ajpath.2006.051191)
technical difficulties in propagating infectious HCV in cell culture. However, the recent development of infectious retroviral pseudotypes bearing HCV glycoproteins (HCVpp) and the robust replication of HCV strain JFH1 in cell culture (HCVcc) have enabled studies on HCV cell entry. HCVpp and HCVcc show a restricted tropism for human liver cell lines, and infection is dependent on CD81 expression. We demonstrated that HCVpp can interact with DC-SIGN- and DC-SIGNR-expressing cells; however, the physiological relevance of these virus-lectin interactions for HCV infection of the liver remains unclear.

Hepatic sinusoidal endothelial cells (HSECs) are unique among endothelial cells in their ability to internalize and process a diverse range of antigens. In contrast to most other endothelial cells, HSECs can process and present antigen to naive CD4 T cells and cross prime CD8 T cells. This latter response may lead to antigen-specific tolerance rather than immunity, suggesting the HSECs may contribute to the tolerogenic properties of the liver. This is of particular relevance in the setting of liver metastases or from organ donors in whom the liver tissue was not used for transplantation.

Isolation and Culture of Human HSECs

Liver endothelial cells were isolated from human liver tissue (surplus to surgical requirements) as previously described using a modified collagenase digestion technique. Briefly, nonparenchymal cells were separated by density gradient centrifugation over metrizamide (Sigma-Aldrich, St. Louis, MO), and endothelial cells were isolated from the resultant heterogeneous cell mixture by positive immunomagnetic selection using antibodies against CD31 (M823, 10 μg/ml; Dako, Ely, UK) and Dynabeads conjugated with goat-anti-mouse monoclonal antibody (Dynal Biotech, Wirral, UK) according to the manufacturer’s protocol.

Maintenance and Culture of HSECs

Following isolation, HSECs were cultured in complete medium composed of human endothelial basal growth medium (Invitrogen, Carlsbad, CA), 10% AB human serum (HD Supplies, Glasgow, UK), and 10 ng/ml vascular endothelial growth factor and 10 ng/ml hepatocyte growth factor (R&D Systems, Minneapolis, MN). The cells were propagated in collagen-coated culture flasks and maintained at 37°C in a humidified 5% CO2 incubator until cells were confluent.

Immunohistochemistry and Dual-Color Co-Immunofluorescence

The following primary antibodies were used: DC-SIGN (MAB161, IgG2b) and DC-SIGNR (MAB162, IgG2b) from R&D Systems, LYMVE-1 (8C, IgG1; a gift from David Jackson, University of Oxford), CD68 (EBM11, IgG1; from Abcam, Cambridge, UK), and mannose receptor (MCA2155, IgG1; from Serotec Ltd., Oxford, UK). 5-μm cryostat sections derived from normal liver were fixed in acetone for 10 minutes and stained using a standard alkaline phosphatase anti-alkaline phosphatase technique. Briefly, primary antibody was followed by rabbit anti-mouse monoclonal and mouse monoclonal alkaline phosphatase anti-alkaline phosphatase (Dako). The stain was developed with fast red and naphthol AS-MX phosphate substrate (Sigma-Aldrich). Sections for dual immunofluorescence were pretreated with staining buffer (phosphate-buffered saline containing 10% fetal calf serum and 0.1% sodium azide) for 10 minutes. Slides were incubated with primary antibodies diluted in staining buffer for 1 hour in a humidified chamber. Control sections were incubated with isotype-matched IgG2b or IgG1 (R&D Systems). Sections were stained with goat anti-mouse IgG2b Alexa Fluor (Molecular Probes, Eugene, OR) and goat anti-mouse IgG1 fluorescein isothiocyanate (Serotec). Immunofluorescence was assessed using AxioVision software (Carl Zeiss MicroImaging, Inc., Jena, Germany).

Materials and Methods

Tissue Studied

Ethics approval for the study was given by the South Birmingham Local Research Ethics Committee (Queen Elizabeth Hospital, Birmingham, UK) and the University Hospital Birmingham Trust (Queen Elizabeth Hospital). All liver tissue was collected with informed consent. Liver tissue from nondiseased liver was used for immunohistochemical studies. Nondiseased liver was obtained either from patients undergoing hemi-hepatectomy to remove liver metastases or from organ donors in whom the liver tissue was not used for transplantation.
Measurement of Cell-Surface Molecules on HSECs

HSECs were plated at $1 \times 10^5$ ml$^{-1}$ and grown to confluence in collagen-coated 96-well flat bottom plates (BD Falcon, Oxford, UK). Cells were left under basal conditions or stimulated with cytokines for 24 hours (10 ng/ml recombinant tumor necrosis factor-$\alpha$ (TNF-$\alpha$), IL-17, IL-10, or 100 ng/ml recombinant IL-4, all from PeproTech, London, UK). Following stimulation the cell monolayers were fixed in methanol. Nonspecific binding of monoclonal antibody (mAb) was inhibited by preincubation of cells for 1 hour at 37°C with 4% goat serum (Sigma) before the addition of mouse-anti-human mAbs (DC-SIGN: MAB161; DC-SIGNR: MAB162 (5 months before the addition of mouse-anti-human mAbs (DC-SIGN: MAB161; DC-SIGNR: MAB162 (5 µg/ml; R&D Systems); E-Selectin: MAB161; DC-SIGNR: MAB162 (5 µg/ml; R&D Systems); E-Selectin: M7105, 1.6 µg/ml; CD31: M0823, 2.25 µg/ml (Dako). The cells were then washed thoroughly before incubation with peroxidase-conjugated goat-anti-mouse secondary Ab (P0447 1/5000; Dako). An enzyme-linked immunosorbent assay was developed using O-phenylenediamine substrate (S2045; Dako) according to the manufacturer’s instructions, and the enzymatic reaction was stopped by using 0.5 mol/L H$_2$SO$_4$ (Fisher Scientific, Leicestershire, UK). Colorimetric analysis was performed by measuring absorbance values at 490 nm using an MRX plate reader (Dynatech Laboratories, Sussex, UK). All treatments were performed in triplicate for each experiment.

Soluble HCV E2 Binding and Blocking Assay

293-T cells were transiently transfected with plasmids expressing HC-J4 E2661 or vector alone (control mock antigen) with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Tissue culture supernatants containing HC-J4 E2661 were harvested 48 hours after transfection, and the amount of HC-J4 E2 antigen was quantified by enzyme immunoassay, as described previously.23 Normal liver sections were preincubated with isotype-matched IgG2b (control block), DC-SIGN, DC-SIGNR (5 µg/ml; R&D Systems), or mannan (20 µg/ml; Sigma-Aldrich) for 1 hour, washed, and then incubated with mock antigen or HC-J4 E2 E661 at a saturating concentration in phosphate-buffered saline/1% fetal bovine serum/0.05% sodium azide/1 mmol/L CaCl$_2$, for 1 hour at room temperature, washed, and labeled with rat anti-E2 mAb 9/75, which recognizes the CD81-binding site on E2 and hence fails to interact with E2-CD81 complexes.33 Detection of binding on normal liver section was as described above using immunofluorescence with goat anti-rat fluorescein isothiocyanate (Serotec). Immunofluorescence was assessed using AxioVision software (Carl Zeiss MicroImaging, Inc.).

Flow Cytometry

HSECs were dissociated from the flask using trypsin (Invitrogen), washed, and preincubated in human immunoglobulins to block Fc receptors. The HCV E2 binding and blocking assay was as described above. The cells were fixed in paraformaldehyde (Sigma-Aldrich), washed, and resuspended in phosphate-buffered saline/10% fetal calf serum before analysis on an Epics XL flow cytometer (Beckman Coulter, Fullerton, CA) using Summit software (DakoCytomation, Glostrup, Denmark).

HCV Pseudoparticle Generation and Infection

HCV pseudoparticles (HCVpp) were generated as previously described.21 Briefly, 293-T cells were cotransfected with pNL4–3.Luc.R–E and a plasmid expressing strain H and HCJ4 E1E2 and vesicular stomatitis virus G protein using Lipofectamine 2000 (Invitrogen). Medium was replaced with Dulbecco’s modified Eagle’s medium/3% fetal bovine serum after 6 hours. Pseudoparticle-containing supernatants were collected after 48 hours and clarified by low speed centrifugation for 10 minutes. For infection experiments target cells were plated into 96-well plates at 1.2 × 10$^4$ per well 24 hours before infection. Pseudoparticle-containing supernatants were diluted in Dulbecco’s modified Eagle’s medium/3% fetal bovine serum with 4 µg/ml Polybrene with or without the desired lipoprotein species. The mixture was incubated at 37°C for 1 hour before being applied to the target cells for 4 to 6 hours. Pseudoparticles were removed, and the cells were incubated for a further 72 hours. Cells were lysed with 40 µl of Cell Culture Lysis Reagent (Promega, Madison, WI), and infection was measured by quantifying the luciferase reporter gene by the addition of 50 µl of luciferase substrate (Promega) using a Centro LB960 luminometer (Berthold Technologies, Bad Wildbad, Germany).

Generation of J6/JFH Virus Stocks and Culturing of Infected Huh-7.5 Cells with Human HSECs

Huh 7.5 cells were trypsinized, harvested by centrifugation (500 × g, 5 minutes), washed twice, and resuspended in ice-cold phosphate-buffered saline at 1.5 × 10$^7$ cells/ml. One microgram of FL-J6/JFH RNA was mixed with 0.4 ml of cells in a 0.2-cm gap cuvette and pulsed using a BTX ElectropSquarePorator (Harvard Apparatus, Hollistion, MA) as described previously.26

Figure 1. HSECs express both DC-SIGN and DC-SIGNR. Immunofluorescence was used to demonstrate the presence of DC-SIGN on HSEC. A: Primary cultures of HSEC-expressed DC-SIGN. B: Cells from the same preparation were also DC-SIGNR-positive.
troporated cells were allowed to recover for 10 minutes at room temperature before the addition of complete media and plated into a 150-mm diameter cell culture dish. After 72 hours, virus containing supernatant was harvested and viral stocks stored at 

Naïve Huh-7.5 cells were infected with J6/JFH at a multiplicity of infection of 0.01, and the cells were maintained in culture for 3 days. The frequency of HCV-infected cells in the culture was investigated by staining cells for the expression of NS5A as previously described. The persistently infected Huh-7.5 culture was mixed 1:4 with primary HSECs, cultured for 48 hours, and stained for HCV NS5A expression.

Results

Expression and Cytokine Regulation of DC-SIGN and DC-SIGNR on HSECs

HSECs were isolated from human liver tissue, propagated in cell culture, and shown to internalize acetylated low density lipoprotein as previously described. Monoclonal antibodies specific for DC-SIGN and DC-SIGNR bound the cultured cells (Figure 1, A and B). Appropriate isotype-matched controls were negative in staining (not shown). DC-SIGN expression during monocyte differentiation is dependent on the cytokine microenvironment. To determine whether cytokines similarly regulate DC-SIGN and DC-SIGNR expression in HSECs, the cells were treated with various cytokines for 24 hours, and lectin expression was measured in a quantitative cell-based immunoassay. IL-4 significantly increased expression of DC-SIGNR (L5, DC-SIGN (DCS), CD31, and E-Selectin (CD62E) by enzyme-linked immunoassorbent assay. An equivalent volume of complete media was added to the control wells. Data represent mean ± SE of four experiments using different HSEC isolates. IL-4 induced a significant increase in DC-SIGNR and DC-SIGN expression (P < 0.05 and P < 0.02; using Student’s t-test).

Figure 2. Treatment with IL-4 increases the expression of DC-SIGNR and DC-SIGN on primary HSEC. HSECs were stimulated with IL-4 (100 ng ml⁻¹), TNF-α (10 ng ml⁻¹), or IL-17 (10 ng ml⁻¹) for 24 hours before assessing expression of DC-SIGNR (LS), DC-SIGN (DCS), CD31, and E-Selectin (CD62E) by enzyme-linked immunosorbent assay. An equivalent volume of complete media was added to the control wells. Data represent mean ± SE of four experiments using different HSEC isolates. IL-4 induced a significant increase in DC-SIGNR and DC-SIGN expression (P < 0.05 and P < 0.02; using Student’s t-test). * P < 0.05; ** P < 0.02.

Figure 3. DC-SIGNR and DC-SIGN on HSECs can bind HCV E2. Binding assays were performed using a strain of HCV HCJ4 with minimal interaction with CD81 when expressed as a truncated E2 species and flow cytometric detection with an antibody raised against E2, which fails to detect E2-CD81 complexes. A: Flow cytometric analysis of HCV E2 binding following treatment with IL-4 (100 ng ml⁻¹ for 24 hours) confirmed that IL-4 significantly increased the expression of both C-type lectins, which led to an increased HCV E2 interaction with the stimulated HSECs (red) compared to unstimulated HSECs (green) and control mock protein in black. B: HCV E2 bound to HSECs (red), and this interaction was inhibited by prior incubation of the cells with mAbs specific for DC-SIGN (gray) and DC-SIGNR (green line) alone or in combination (blue). Control binding with mock protein is in black.

Figure 4. DC-SIGNR and DC-SIGN expression in liver tissue. The left panel is a representative immunofluorescent staining (original magnification, ×10) showing DC-SIGNR is not expressed on portal tracts (PT) as shown with alkaline phosphatase anti-alkaline phosphatase staining on the right panel (original magnification, ×20). DC-SIGN, however, does not have a patchy distribution and is expressed around portal tracts. CV, central vein.

Conclusions

Troporated cells were allowed to recover for 10 minutes at room temperature before the addition of complete media and plated into a 150-mm diameter cell culture dish. After 72 hours, virus containing supernatant was harvested and viral stocks stored at −80°C. Naïve Huh-7.5 cells were infected with J6/JFH at a multiplicity of infection of 0.01, and the cells were maintained in culture for 3 days. The frequency of HCV-infected cells in the culture was investigated by staining cells for the expression of NS5A as previously described. The persistently infected Huh-7.5 culture was mixed 1:4 with primary HSECs, cultured for 48 hours, and stained for HCV NS5A expression.
marker, and E-Selectin were included as positive controls.

Expression of Functionally Active DC-SIGN and DC-SIGNR on HSECs

To determine whether these lectins are able to interact with high mannose-containing glycoproteins we tested their ability to bind a truncated version of HCV E2, previously reported to interact with DC-SIGN and DC-SIGNR. Since HCV E2 interacts with the viral co-receptor CD81, which is also expressed on HSECs (data not shown), we selected a strain of HCV HCJ4 that shows minimal interaction with CD81 when expressed as a truncated E2 species and detected cell-bound E2 with a mAb that fails to detect E2 when complexed with CD81. The IL-4-stimulated expression of DC-SIGN and DC-SIGNR induced a concomitant increase in HCV E2 binding, further supporting the cytokine regulation of these functionally active C-type lectins on HSECs (Figure 3A). HCV E2 binding to IL-4-stimulated HSECs could be inhibited by prior incubation of the cells with mAbs specific for either DC-SIGN or DC-SIGNR. Preincubation with combinations of both DC-SIGN and DC-SIGNR mAbs did not alter the inhibition of HCV E2 binding seen with the single mAb alone (Figure 3B). The finding of complete block with each antibody is surprising. One possible interpretation derives from the observation that these lectins exist as tetramers at the cell surface. Our finding that primary HSECs express both receptors may support a model for hetero-oligomer formation between the two related lectins, which may explain our observations with antibody blocking HCV E2 to these primary cell types. We have shown previously that the mAbs used in this study bind specifically to 293-T cells transduced to express the appropriate receptors.

DC-SIGN and DC-SIGNR Expression in Liver Tissue

To evaluate the distribution of these lectins in normal human liver we examined the ability of DC-SIGN- and DC-SIGNR-specific mAbs to react with cells within tissue sections by immunohistochemistry. The staining pattern of the two receptors differed: DC-SIGNR was only expressed within the liver sinusoids, whereas DC-SIGN was detected on portal tracts in addition to the hepatic sinusoidal endothelium (Figure 4). DC-SIGN and DC-SIGNR expression by endothelial cells in the sinusoids was confirmed by dual staining with anti-LYVE-1 antibody, which selectively stains sinusoidal endothelial cells in human liver (Figure 5). DC-SIGN expression on Kupffer cells was demonstrated by dual staining with the macrophage mannose receptor-positive cells and CD68 (Figure 6). There appear to be differences in the intensity of DC-SIGN-R staining across the sinusoidal bed with a relatively weaker staining in the periportal sinusoids. This may reflect differences in the local microenvironment, a conclusion that is supported by the observations that other proteins, including adhesion molecules, are differentially expressed across hepatic sinusoids. Appropriate isotype-matched controls were negative in staining (data not shown).

To assess whether DC-SIGN and DC-SIGNR expressed in normal liver are able to interact with HCV E2, intact liver sections were incubated with truncated E2 from HC-J4 E2661 and bound antigen visualized with rat anti-E2 antibody 9/75, which recognizes the CD81-binding site on E2 and hence fails to interact with E2-CD81 complexes. E2 bound diffusely and in focal areas within the sinusoids, and binding could be inhibited by mannan, a sugar molecule reported to interact with the carbohydrate recognition sites of C-type lectins (Figure 7, A and B). To confirm the identity of cells that bound HCV E2, sections were counterstained with mAbs specific for macrophage mannose receptor, CD68, and DC-SIGNR (Figure 8, A and B). These data confirm that HCV E2 interacts with both Kupffer and sinusoidal endothelial...
cells within the liver, consistent with the pattern of DC-SIGN and DC-SIGNR expression. To confirm that HCV E2 binding was dependent on DC-SIGN and DC-SIGNR expression, liver sections were preincubated with mAbs specific for DC-SIGN and DC-SIGNR and evaluated for their ability to bind HCV E2. Pretreatment of liver sections with a control isotype-matched IgG2b mouse immunoglobulin had no effect on E2 binding (Figure 9A). The mAb specific for DC-SIGN inhibited E2 binding to both Kupffer and sinusoidal cells (Figure 9B), whereas the mAb specific for DC-SIGNR only attenuated E2 binding to sinusoidal cells (Figure 9C). However, we also used E2 derived from HCV strain H77, which binds with high affinity to CD81. To distinguish E2-H77 interacting with CD81 and the lectins DC-SIGN(R), we used two anti-E2 mAbs that could discriminate between E2 bound to CD81. These experiments allowed us to confirm the results we obtained with E2-HCJ4 with an independent strain of E2 (data not shown). These data conclusively show DC-SIGN and DC-SIGNR expressed in normal liver are able to interact with HCV E2.

HSECs Do Not Support HCV Infection

As a model for studying HCV interaction with DC-SIGN/DC-SIGNR in the liver, several investigators have expressed DC-SIGN and DC-SIGNR in heterologous cell systems and studied HCVpp interactions.4–6,35 HCVpp fails to infect cells engineered to express DC-SIGN and DC-SIGNR; however, infectivity can be transferred to permissive hepatoma cells,41,42 suggesting that these lectin molecules may act as ‘transfer receptors’ within the liver, enabling endothelial cells to ‘trap and concentrate’ HCV within the sinusoids and to transfer virus to the permissive underlying hepatocytes. However, the assumption that DC-SIGN/DC-SIGNR expressed in heterologous cells accurately mimics primary HSEC lectin-dependent interactions with HCV is undermined by a recent report43 that DC-SIGN interaction with human immunodeficiency virus is dependent on the cellular context. To address this issue we purified HSECs from three donor livers, confirmed CD81, DC-SIGN, and DC-SIGNR expression, and evaluated their ability to support HCVpp entry. Virus entry and uncoating is quantified by luciferase expression in the target cell under the control of the retroviral promoter and is directly proportional to the frequency of infected cells.21 Pseudotypic particles with no envelope glycoproteins were used to control for nonspecific particle uptake and viruses expressing vesicular stomatitis virus G served as a control for retroviral RNA transcription and translation of the luciferase reporter gene within the primary cells. HCVpp bearing strain HCJ4 and H77 glycoproteins infected Hep3B hepatoma cells and primary human hepatocytes but failed to infect HSECs (Figure 10). Vesicular stomatitis virus pseudoparticle infected all
target cells with different efficiencies, and particles with no envelope glycoproteins gave background signals comparable to uninfected cells. Treatment of HSECs with IL-4 24 hours before infection did not alter the results. To establish whether J6/JFH HCVcc could infect HSECs, we cocultured J6/JFH-infected Huh-7.5 cells with primary HSECs. After 48 hours, HCV infection in the isolated and cocultured cells was determined by immunostaining for HCV NS5A antigen. Viral antigen was only detected in the Huh-7.5 cells and not within the coculture (Figure 11), consistent with primary HSECs failing to support HCVpp infection.

Discussion

Our findings demonstrate that human HSECs express DC-SIGNR and DC-SIGN in vivo and that both receptors can interact with HCV E2. Expression of DC-SIGN by HSECs provides further evidence for the ability of HSECs to process and present microbial antigens. We show that primary HSECs are unable to support HCVpp and HCVcc entry. These data are consistent with a model where DC-SIGN and DC-SIGNR on sinusoidal endothelium provide a mechanism for high affinity binding of circulating HCV within the liver sinusoids allowing transfer of the virus to underlying hepatocytes, in a manner analogous to dendritic cell DC-SIGN presenting HIV to T lymphocytes.41 Viral capture at the cell surface can be rate limiting for infection,11,44,45 suggesting that expression of both DC-SIGN and DC-SIGNR on HSECs may enhance the rate and efficiency of virus infection of hepatocytes expressing the coreceptors, CD81 and scavenger receptor Bl.11,46 DC-SIGN is able to recognize highly mannosylated glycoproteins at the surface of a broad range of pathogens, including viruses, bacteria, fungi, and parasites.47,48 For at least some of these agents, this interaction appears to be an important component of the infection process, as demonstrated for human immunodeficiency virus and Ebola virus, making DC-SIGN an attractive target for drug design.47,49,50 Glycodendritic polymers that block the binding of pathogen glycoproteins to DC-SIGN inhibit DC-SIGN-mediated infection in an Ebola-pseudotyped viral model.47,49 In addition, these lectins may provide a viral escape mechanism as uptake of HCV by DC-SIGN and DC-SIGNR has been reported to target nonlysosomal compartments in immature DCs, whereas Lewis X antigen, another ligand of DC-SIGN, was internalized to lysosomes.51 Thus, DC-SIGN and DC-SIGNR on HSECs may not only act to capture HCV from blood but may also allow HSECs to act as reservoirs for HCV, allowing the virus to avoid detection and to be transmitted to the underlying hepatocyte, the primary target for HCV.

The detection of functional DC-SIGN on HSECs is further evidence of the unique antigen-capturing and -scavenging properties of these cells. HSECs can act as organ-resident, nonmyeloid antigen processing cells by cross-presenting soluble exogenous antigen to CD8+ T cells using similar mechanisms of antigen processing and presentation as dendritic cells. However, the outcome of cross-presentation by HSECs is CD8+ T cell tolerance, and major histocompatibility class II-restricted antigen presentation by HSECs to naive CD4+ T cells leads to differentiation into IL-4/IL-10-expressing Th2 cells.30,52 The presence of DC-SIGN on HSECs may allow these cells to capture and endocytose a range of microbial pathogens for subsequent presentation to the immune system. Furthermore, DC-SIGN can also act as an adhesion receptor to support interactions with intercellular adhesion molecule-3 on T cells during antigen presentation and on dendritic cells during transendothelial migration, extending the potential role of HSECs in immune responses.
We found that IL-4 but not IL-12, interferon-γ, TNF-α, or IL-17 increased expression of DC-SIGN on HSECs in vitro. IL-4 has been shown to increase expression of DC-SIGN on monocytes and THP-1 cells.\(^\text{34,35}\) In monocytes IL-4 treatment favors differentiation into dendritic cells rather than macrophages.\(^\text{34,35}\) And evidence suggests that IL-4 is the key cytokine for DC-SIGN acquisition during monocyte-derived dendritic cell differentiation. Our findings provide evidence that DC-SIGN expression is IL-4-dependent in endothelial cells as well as myeloid cells, although we did not see suppression of DC-SIGN by TNF-α treatment as reported with macrophages.\(^\text{34,35}\) The lack of response to IL-12 and interferon-γ suggests that induction of DC-SIGN on HSECs will be promoted by Th2 rather than Th1 cytokine responses consistent with the requirement for vigorous Th1 responses to clear viral infection.

In conclusion, this report is the first description of DC-SIGN expression on sinusoidal endothelium and provides evidence of the unique antigen-processing and scavenging properties of these cells. The distinct distribution of DC-SIGN and DC-SIGNR in the liver and the ability of both lectins to bind HCV E2 in vivo suggest a complementary role in trapping HCV within the hepatic sinusoids. The up-regulation of DC-SIGN and DC-SIGNR by IL-4 suggests that the local cytokine microenvironment may affect HCV cell attachment and infectivity.

**Acknowledgment**

We thank Charles Rice (Rockefeller University) for the provision of the J6/JFH and anti-NS5A monoclonal antibody.

**References**

2. Gardiner JP, Durso RJ, Agrigale RR, Donovan GP, Maddon PJ, Dragic T, Olson WC: L-SIGN (CD209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci USA 2003, 100:4498–4503
43. Trumpfeller C, Park CG, Finke J, Steinman RM, Granelli-Piperno A: Type 1 cell-dependent retention and transmission of HIV-1 by DC-SIGN. Int Immunol 2003, 15:289–298